Comparative Pharmacology
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE versus HYDROFLUMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE versus HYDROFLUMETHIAZIDE.
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE vs HYDROFLUMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azilsartan medoxomil is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Chlorthalidone is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing sodium and water excretion.
Hydroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg or 25 mg orally once daily; maximum dose: azilsartan medoxomil 40 mg/chlorthalidone 25 mg per day.
Oral: 25-50 mg once daily; may increase to 100 mg/day in divided doses if needed.
None Documented
None Documented
Clinical Note
moderateHydroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin."
Clinical Note
moderateHydroflumethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin."
Clinical Note
moderateHydroflumethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Deslanoside."
Clinical Note
moderateAzilsartan medoxomil: Terminal half-life approximately 11 hours. Chlorthalidone: Long terminal half-life of 40-60 hours (mean 47 hours), allowing once-daily dosing.
Terminal elimination half-life of 6-9 hours in patients with normal renal function; clinically, this supports once-daily dosing in hypertension but may require twice-daily dosing in some patients with impaired renal function
Azilsartan medoxomil: Approximately 55% of the dose is excreted in feces and 42% in urine, mostly as metabolites. Chlorthalidone: Primarily excreted unchanged in urine (50-70%) via tubular secretion; approximately 30% is excreted in feces via biliary elimination.
Primarily renal (approximately 85% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Hydroflumethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Acetyldigitoxin."